CellCentric operates at the intersection of biotechnology and pharmaceuticals, with a focus on developing innovative therapeutic solutions and advancing life sciences research. Given the company’s current stage, European benchmarks (Q1 2026) for biotechnology and pharmaceutical businesses indicate valuation ranges of EV/Sales multiples of 3.61x – 4.99x, and EV/EBITDA multiples of 17.86x – 20.68x.
